Valesca P. Retel

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 134 publications

Human epididymis protein 4 and risk of malignancy index as risk assessment tools in the decision for referral to an oncology center in patients with an ovarian mass: a cost-effectiveness analysis from a Dutch health care perspective.

Human epididymis protein 4 and risk of malignancy index as risk assessment tools in the decision for referral to an oncology center in patients with an ovarian mass: a cost-effectiveness analysis from a Dutch health care perspective.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: February 21, 2026

Hospital-based real-world evidence in health technology assessment: insights from a scoping review of European, Australian and North American guidance and expert interviews.

Hospital-based real-world evidence in health technology assessment: insights from a scoping review of European, Australian and North American guidance and expert interviews.

Journal: BMJ open

Published: December 31, 2025

Budget Impact Analysis of Hyperthermic Intraperitoneal Chemotherapy With Interval Cytoreductive Surgery in Ovarian Cancer.

Budget Impact Analysis of Hyperthermic Intraperitoneal Chemotherapy With Interval Cytoreductive Surgery in Ovarian Cancer.

Journal: JCO oncology practice

Published: December 19, 2025

Economic Evaluation of Comprehensive Genomic Profiling in an Advanced Solid Cancer Population.

Economic Evaluation of Comprehensive Genomic Profiling in an Advanced Solid Cancer Population.

Journal: JAMA network open

Published: December 11, 2025

A comparative analysis of managed entry agreements in Europe: trends, reporting practices, and financial outcomes.

A comparative analysis of managed entry agreements in Europe: trends, reporting practices, and financial outcomes.

Journal: The European journal of health economics : HEPAC : health economics in prevention and care

Published: December 05, 2025

Hepatic arterial infusion pump chemotherapy combined with systemic therapy versus systemic therapy alone as induction treatment for initially unresectable colorectal liver metastases: a study protocol of the randomised controlled trial - PUMP-IT RCT.

Hepatic arterial infusion pump chemotherapy combined with systemic therapy versus systemic therapy alone as induction treatment for initially unresectable colorectal liver metastases: a study protocol of the randomised controlled trial - PUMP-IT RCT.

Journal: BMC cancer

Published: December 02, 2025

Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis.

Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis.

Journal: The Lancet. Oncology

Published: November 20, 2025

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: November 20, 2025

Price transparency of cancer medicines: a crucial step towards informed pricing negotiations in the European region.

Price transparency of cancer medicines: a crucial step towards informed pricing negotiations in the European region.

Journal: Frontiers in pharmacology

Published: November 03, 2025

Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors.

Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors.

Journal: Clinical drug investigation

Published: June 04, 2025

Toward a validated European instrument to measure the socioeconomic impact of cancer.

Toward a validated European instrument to measure the socioeconomic impact of cancer.

Journal: International journal of cancer

Published: April 03, 2025

A Value-Based Evaluation Framework for Guiding the Adoption and Scale-Up of Cancer Genomics Interventions.

A Value-Based Evaluation Framework for Guiding the Adoption and Scale-Up of Cancer Genomics Interventions.

Journal: Public health genomics

Published: April 01, 2025

Showing 1-12 of 134

Last Updated: 09/26/2026